Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease
申请人:——
公开号:US20030073707A1
公开(公告)日:2003-04-17
The invention provides compounds of Formula I:
1
wherein W
0
is a bicyclic moiety and is
2
These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful to treat diseases or conditions in which &agr;7 is known to be involved.
2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
申请人:Peyronel Jean-Francois
公开号:US20100317688A1
公开(公告)日:2010-12-16
Compounds of formula (I):
in which:
X, R
1
, R
2
, R
3
, and R
4
are as defined in the disclosure, or an acid addition salt thereof; an therapeutic use thereof.
式(I)的化合物:
其中:
X,R1,R2,R3和R4如披露中所定义,或其酸盐;其治疗用途。
2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
申请人:PEYRONEL Jean-Francois
公开号:US20100317687A1
公开(公告)日:2010-12-16
Compounds of formula (I)
in which:
X, R
1
, R
2
, R
3
, and R
4
are as defined in the disclosure, or an acid addition salt thereof; and therapeutic use thereof.
其中:
X,R1,R2,R3和R4如披露中所定义的化合物的公式(I),或其酸盐;以及其治疗用途。
[EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF HEPATITIS C<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DE L'HÉPATITE C
申请人:MERCK SHARP & DOHME
公开号:WO2014205592A1
公开(公告)日:2014-12-31
Compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system are disclosed.
[EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS MÉTHODES D'UTILISATION POUR LE TRAITEMENT DE L'HÉPATITE C
申请人:MERCK SHARP & DOHME
公开号:WO2014209729A1
公开(公告)日:2014-12-31
The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.(I)